Johnson & Johnson $JNJ Stake Decreased by Yacktman Asset Management LP

Yacktman Asset Management LP lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,287,234 shares of the company’s stock after selling 76,300 shares during the quarter. Johnson & Johnson makes up approximately 3.3% of Yacktman Asset Management LP’s portfolio, making the stock its 9th largest holding. Yacktman Asset Management LP owned about 0.05% of Johnson & Johnson worth $238,679,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson in the second quarter valued at $27,000. Clayton Financial Group LLC purchased a new stake in Johnson & Johnson in the 3rd quarter worth about $28,000. Semmax Financial Advisors Inc. raised its stake in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares during the period. GFG Capital LLC purchased a new stake in Johnson & Johnson during the second quarter valued at about $35,000. Finally, Signature Resources Capital Management LLC boosted its position in Johnson & Johnson by 262.9% during the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after purchasing an additional 184 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $230.82 on Tuesday. The stock has a market cap of $556.11 billion, a price-to-earnings ratio of 20.89, a PEG ratio of 2.21 and a beta of 0.35. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The business has a 50-day simple moving average of $211.21 and a 200 day simple moving average of $192.24. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $231.19.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, meeting the consensus estimate of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The firm had revenue of $24.56 billion for the quarter, compared to analysts’ expectations of $24.14 billion. During the same quarter last year, the firm posted $2.04 EPS. The company’s revenue was up 9.1% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s payout ratio is currently 47.06%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on JNJ. Argus boosted their price target on shares of Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Bank of America lifted their price target on Johnson & Johnson from $220.00 to $221.00 and gave the company a “neutral” rating in a research report on Thursday, January 22nd. Citigroup increased their price objective on Johnson & Johnson from $232.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Finally, Wolfe Research lifted their target price on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $233.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.